drugset / Trial / NCT03164486
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Phase 0
Active not recruiting
27 enrolled
Julie L. Sutcliffe, Ph.D
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Timeline
- Start
- 2016-11
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-αvβ6-BP | Diagnostic / imaging agent | 370 mbq | Intravenous |